These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9189907)
21. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282 [TBL] [Abstract][Full Text] [Related]
23. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877 [TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Royston MC; Mann D; Pickering-Brown S; Owen F; Perry R; Raghavan R; Khin-Nu C; Tyrer S; Day K; Crook R Neuroreport; 1994 Dec; 5(18):2583-5. PubMed ID: 7696609 [TBL] [Abstract][Full Text] [Related]
25. Association between serum beta-carotene levels and decline of cognitive function in high-functioning older persons with or without apolipoprotein E 4 alleles: MacArthur studies of successful aging. Hu P; Bretsky P; Crimmins EM; Guralnik JM; Reuben DB; Seeman TE J Gerontol A Biol Sci Med Sci; 2006 Jun; 61(6):616-20. PubMed ID: 16799145 [TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Bartzokis G; Lu PH; Geschwind DH; Edwards N; Mintz J; Cummings JL Arch Gen Psychiatry; 2006 Jan; 63(1):63-72. PubMed ID: 16389198 [TBL] [Abstract][Full Text] [Related]
27. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Bunce D; Fratiglioni L; Small BJ; Winblad B; Bäckman L Neurology; 2004 Sep; 63(5):816-21. PubMed ID: 15365129 [TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. Yip AG; Brayne C; Easton D; Rubinsztein DC; J Med Genet; 2002 Sep; 39(9):639-43. PubMed ID: 12205106 [TBL] [Abstract][Full Text] [Related]
29. Editorial: pharmacological intervention for Down syndrome cognitive deficits: emerging drug targets. Montesinos ML CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):6-7. PubMed ID: 24152331 [No Abstract] [Full Text] [Related]
30. Effect of plasma lipids, hypertension and APOE genotype on cognitive decline. Yasuno F; Tanimukai S; Sasaki M; Ikejima C; Yamashita F; Kodama C; Hidaka S; Mizukami K; Asada T Neurobiol Aging; 2012 Nov; 33(11):2633-40. PubMed ID: 22285757 [TBL] [Abstract][Full Text] [Related]
31. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Ballard CG; Morris CM; Rao H; O'Brien JT; Barber R; Stephens S; Rowan E; Gibson A; Kalaria RN; Kenny RA Neurology; 2004 Oct; 63(8):1399-402. PubMed ID: 15505155 [TBL] [Abstract][Full Text] [Related]
32. A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing. van Gool WA; Evenhuis HM; van Duijn CM Ann Neurol; 1995 Aug; 38(2):225-30. PubMed ID: 7654070 [TBL] [Abstract][Full Text] [Related]
33. Interactive effect of APOE genotype and blood pressure on cognitive decline: the PATH through life study. Andrews S; Das D; Anstey KJ; Easteal S J Alzheimers Dis; 2015; 44(4):1087-98. PubMed ID: 25672766 [TBL] [Abstract][Full Text] [Related]
35. Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive disorders. Kahlem P Behav Genet; 2006 May; 36(3):416-28. PubMed ID: 16557362 [TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E ɛ4, Cognitive Function, and Pain Experience in Down Syndrome: A Pilot Study. de Knegt NC; Schuengel C; Evenhuis HM; Lobbezoo F; Scherder EJ Arch Clin Neuropsychol; 2016 Aug; 31(5):389-400. PubMed ID: 27193365 [TBL] [Abstract][Full Text] [Related]
37. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]. Asai M; Kawakubo T; Mori R; Iwata N Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290 [TBL] [Abstract][Full Text] [Related]
38. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Wolvetang EW; Bradfield OM; Tymms M; Zavarsek S; Hatzistavrou T; Kola I; Hertzog PJ Biochim Biophys Acta; 2003 Jul; 1628(2):105-10. PubMed ID: 12890557 [TBL] [Abstract][Full Text] [Related]
39. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. Kurz MW; Dekomien G; Nilsen OB; Larsen JP; Aarsland D; Alves G J Geriatr Psychiatry Neurol; 2009 Sep; 22(3):166-70. PubMed ID: 19321880 [TBL] [Abstract][Full Text] [Related]